JP2024532882A - Gdf15融合タンパク質及びその使用 - Google Patents

Gdf15融合タンパク質及びその使用 Download PDF

Info

Publication number
JP2024532882A
JP2024532882A JP2024512156A JP2024512156A JP2024532882A JP 2024532882 A JP2024532882 A JP 2024532882A JP 2024512156 A JP2024512156 A JP 2024512156A JP 2024512156 A JP2024512156 A JP 2024512156A JP 2024532882 A JP2024532882 A JP 2024532882A
Authority
JP
Japan
Prior art keywords
seq
amino acid
fusion protein
gdf15
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532882A5 (cg-RX-API-DMAC7.html
Inventor
ジアンユ・ヤン
ロンボ・カオ
リン・シャオ
ジュンナン・ゼン
リメイ・フアン
シリン・ウェイ
ジャオフェン・リ
チンウェイ・ゴン
シングオ・ヤン
ジン・リ
ダンシア・フアン
シャオフェン・チェン
ウェンジア・リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of JP2024532882A publication Critical patent/JP2024532882A/ja
Publication of JP2024532882A5 publication Critical patent/JP2024532882A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024512156A 2021-08-24 2022-08-23 Gdf15融合タンパク質及びその使用 Pending JP2024532882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110977378.7 2021-08-24
CN202110977378 2021-08-24
PCT/CN2022/114096 WO2023025120A1 (en) 2021-08-24 2022-08-23 Gdf15 fusion proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532882A true JP2024532882A (ja) 2024-09-10
JP2024532882A5 JP2024532882A5 (cg-RX-API-DMAC7.html) 2025-08-07

Family

ID=85321545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512156A Pending JP2024532882A (ja) 2021-08-24 2022-08-23 Gdf15融合タンパク質及びその使用

Country Status (8)

Country Link
US (3) US20240350588A1 (cg-RX-API-DMAC7.html)
EP (3) EP4393941A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532882A (cg-RX-API-DMAC7.html)
KR (1) KR20240049337A (cg-RX-API-DMAC7.html)
CN (3) CN115925982A (cg-RX-API-DMAC7.html)
AU (1) AU2022333099A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226178A1 (cg-RX-API-DMAC7.html)
WO (3) WO2023025120A1 (cg-RX-API-DMAC7.html)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014104165A1 (ja) * 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP2016526909A (ja) * 2013-07-31 2016-09-08 アムジエン・インコーポレーテツド Fc含有ポリペプチドの安定化
JP2016532690A (ja) * 2013-07-31 2016-10-20 アムジエン・インコーポレーテツド 増殖分化因子15(gdf−15)の構築物
JP2017518965A (ja) * 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたFc構築物に関連する組成物および方法
WO2020086758A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
JP2020533271A (ja) * 2018-04-09 2020-11-19 アムジエン・インコーポレーテツド 増殖分化因子15融合タンパク質
WO2021107603A2 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2021119832A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
JP2021517584A (ja) * 2018-04-06 2021-07-26 イーライ リリー アンド カンパニー 増殖分化因子15アゴニスト化合物およびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101374454B1 (ko) * 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Fc領域を含むモノマーポリペプチド及び使用方法
KR20140125803A (ko) * 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
BR112021021271A2 (pt) * 2019-04-23 2021-12-21 Lg Chemical Ltd Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15
BR112022007128A2 (pt) * 2019-10-15 2022-07-05 Dragonfly Therapeutics Inc Ligação de proteínas nkg2d, cd16 e flt3
EP4458863A1 (en) * 2021-12-31 2024-11-06 Sunshine Lake Pharma Co., Ltd. Fusion protein of glp-1 and gdf15 and use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014104165A1 (ja) * 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
JP2016526909A (ja) * 2013-07-31 2016-09-08 アムジエン・インコーポレーテツド Fc含有ポリペプチドの安定化
JP2016532690A (ja) * 2013-07-31 2016-10-20 アムジエン・インコーポレーテツド 増殖分化因子15(gdf−15)の構築物
JP2017518965A (ja) * 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたFc構築物に関連する組成物および方法
JP2021517584A (ja) * 2018-04-06 2021-07-26 イーライ リリー アンド カンパニー 増殖分化因子15アゴニスト化合物およびその使用方法
JP2020533271A (ja) * 2018-04-09 2020-11-19 アムジエン・インコーポレーテツド 増殖分化因子15融合タンパク質
WO2020086758A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
WO2021107603A2 (en) * 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
WO2021119832A1 (en) * 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same

Also Published As

Publication number Publication date
US20240350588A1 (en) 2024-10-24
EP4393941A4 (en) 2025-10-15
AU2022333099A1 (en) 2024-02-08
KR20240049337A (ko) 2024-04-16
CN115925982A (zh) 2023-04-07
CA3226178A1 (en) 2023-03-02
EP4393941A1 (en) 2024-07-03
WO2023025120A1 (en) 2023-03-02
CN115925983A (zh) 2023-04-07
CN115925984A (zh) 2023-04-07
EP4393940A1 (en) 2024-07-03
WO2023025129A1 (zh) 2023-03-02
EP4392461A4 (en) 2025-10-15
EP4393940A4 (en) 2025-10-15
US20240391971A1 (en) 2024-11-28
EP4392461A1 (en) 2024-07-03
WO2023025123A1 (zh) 2023-03-02
US20240343770A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
EP3144320B1 (en) Fc fusion proteins comprising novel linkers or arrangements
KR102085605B1 (ko) 대사 장애를 치료하기 위한 융합 단백질
KR102668200B1 (ko) 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP1280826B1 (en) Polypeptides for inhibiting april-mediated b- and t-cell proliferation.
JP7064618B2 (ja) 増殖分化因子15アゴニスト化合物およびその使用方法
CN108570109A (zh) 包含免疫球蛋白Fc部分的双靶点融合蛋白
WO2005040217B1 (en) Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
RU2715606C2 (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
CN114591415A (zh) Glp-1/gcg双受体激动剂多肽及其融合蛋白
TWI889865B (zh) 包含類升糖素胜肽-1及介白素-1受體拮抗物的融合蛋白及其用途
WO2023280133A1 (zh) 融合蛋白及其应用
KR20220157910A (ko) Gdf15 변이체 및 glp-1 수용체 작용제를 포함하는 병용 투여용 조성물
JP2025504612A (ja) Glp-1及びgdf15の融合タンパク質並びにその使用
WO2023025120A1 (en) Gdf15 fusion proteins and uses thereof
CN113861291A (zh) VEGF-trap多肽及其应用
WO2008032059A2 (en) Growth factor
NZ734482B2 (en) Fc FUSION HIGH AFFINITY IgE RECEPTOR a-CHAIN
HK1244016B (en) Fc fusion high affinity ige receptor α-chain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526